GBL stock holds above EUR 72 as private equity deal highlights portfolio value

GBL stock is trading in the low EUR 70s on Euronext Brussels as investors weigh recent price weakness against the value highlighted by a major private equity-backed take-private in its portfolio.

Groupe Bruxelles Lambert (GBL, ISIN BE0003797140) stock is trading around EUR 72 on Euronext Brussels on August 20, 2026, after a period of modest share price weakness so far this year. Per recent market data, the shares last changed hands at EUR 72.80, with the one-year trading range running from EUR 71.30 to EUR 85.65, indicating that the current level is closer to the lower end of the past-year band. The stock is down 4.28% since January 1, 2026, underscoring how the discount to net asset value remains a key part of the investment case.

Share performance and valuation context

Recent quote data compiled by a European market portal shows that GBL closed at EUR 72.80 on August 20, 2026, a gain of 0.14% on the day after opening at EUR 72.50 and trading between an intraday high of EUR 72.95 and a low of EUR 72.40. Over the past month the share price has declined 5.71%, with a high of EUR 79.90 and a low again around EUR 72.40, while the three-month performance is a negative 8.44% with the same EUR 72.40 level acting as the bottom of the range. Since the beginning of 2026, the shares have fallen 4.28%, compared with a five-year change of -25.16% that saw a peak at EUR 105.05 and a floor near EUR 61.55. These figures highlight how the current level around EUR 72 is below the mid-point of the multi-year range and still reflects a sizeable valuation discount versus the company’s reported net asset value per share.

The same market overview indicates a market capitalization for GBL of EUR 9.22 billion as of the latest data, providing investors with a reference for the size of the diversified investment holding company. On the income side, the dividend per share has steadily increased, with reported historical payments of EUR 1.93 for fiscal 2023 and EUR 3.50 for fiscal 2024, and consensus expectations pointing to EUR 5.12 in 2025 and EUR 5.24 in 2026. Given the current share price around EUR 72.80, a projected dividend of EUR 5.12 would imply a forward dividend yield of 7.03%, a marked increase from the 5.30% yield associated with the EUR 3.50 dividend in 2024. This quantified comparison between past and expected distributions helps explain why income-focused investors continue to pay attention to the stock despite the lack of strong price momentum year to date.

Fundamentals and dividend outlook

According to an earnings and dividend table provided by a financial portal, GBL reported earnings per share of EUR 12.28 for fiscal 2023 and EUR 0.99 for fiscal 2024, illustrating how results can fluctuate significantly depending on realized gains, impairments, and the mark-to-market performance of the underlying portfolio. At a share price near EUR 72.80, the trailing price-earnings ratio based on the EUR 12.28 per-share figure stands at 5.93, while using the EUR 0.99 value for 2024 implies a much higher multiple above 70, showing that single-year earnings do not fully capture the company’s long-term earnings capacity. Historically, the book value per share has been around EUR 112.53, implying that the stock trades at a price-to-book ratio close to 0.65 using this reference point, which signals a substantial discount to the book value of the portfolio holdings.

The same compiled estimates suggest that consensus expects earnings per share of EUR 3.44 in 2025 and EUR 3.40 in 2026. At the current share price, those figures correspond to forward price-earnings ratios of roughly 21.16 and 21.41 respectively, underlining that the market values GBL more on the stability and yield of its diversified assets and dividends than on any single year’s reported profit. The combination of an expected dividend of EUR 5.12 for 2025 and a share price of EUR 72.80 results in a forward dividend yield above 7%, which compares favorably with the 2.70% yield based on the EUR 1.93 dividend recorded in 2023. For investors, this step-up in the cash return profile is one of the main reasons why the shares, despite trading below book value, can still provide an attractive total-return proposition.

Private equity deal underlines portfolio relevance

Beyond the basic valuation metrics, GBL’s role as a long-term investor in European companies has been underscored by a recent series of large private equity transactions in the region. A private equity market commentary published on August 19, 2026 highlights that the Europe, Middle East and Africa region saw three of the four largest global private equity deals in the second quarter of 2026, including the take-private of Italy-based pharmaceutical group Recordati by funds advised by CVC Capital Partners alongside GBL. This transaction, valued at $14.6 billion for a separate UK target and $12.5 billion for another German target, illustrates the scale at which GBL operates when co-investing in major European corporates. By participating in such a take-private, the holding company reinforces its position as an influential shareholder in the European healthcare sector and demonstrates the ability to work alongside global private equity firms to unlock value.

For shareholders, the Recordati deal is significant because it shows how GBL can recycle capital from listed holdings into new opportunities that may later generate higher returns, whether through future stock market listings or strategic sales. While the immediate earnings impact of the transaction will depend on the structure and financing, the involvement in a multi-billion-dollar deal signals that the company is active in reshaping its portfolio and not merely passively holding stakes. This kind of activity supports the case that the discount of the share price to book value and net asset value can gradually narrow if the market gains confidence in the group’s ability to crystallize value in underlying assets.

Representative portfolio exposure: Recordati

One representative exposure in GBL’s portfolio is Recordati, the Italian pharmaceutical company that has been the subject of the recent take-private by private equity funds working alongside the Belgian holding company. Recordati is known for its focus on specialty and rare disease treatments, generating revenues across Europe and international markets through a mix of original brands and licensed products. Its business model emphasizes recurring prescription revenues, a pipeline of niche therapies, and disciplined cost management, which together produce solid margins and cash flows that are attractive to long-term investors such as GBL. By aligning with private equity partners, GBL aims to support Recordati’s growth plans, including potential geographic expansion and further development of its product portfolio, while also creating the possibility of future value realization events.

GBL stock and investor takeaway

GBL stock continues to trade on Euronext Brussels in the low EUR 70s, with a last reported price of EUR 72.80 as of August 20, 2026. With a market capitalization of EUR 9.22 billion and a projected forward dividend of EUR 5.12 per share that implies a yield above 7% at the current price, the shares offer a combination of income and exposure to a curated portfolio of European businesses, including high-profile targets for private equity-backed transactions such as Recordati.

Fact box

Company: Groupe Bruxelles Lambert S.A.

ISIN: BE0003797140

Ticker: GBLB

Exchange: Euronext Brussels

Price (as of August 20, 2026, 11:23 a.m. CET): EUR 72.80

Market cap: EUR 9.22 billion (as of August 20, 2026)

Sector / Industry: Financials / Investment holdings

Index membership: BEL 20